Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2024

This “Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2024” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Anti-CD279 (PD-1) Antibody pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Anti-CD279 (PD-1) Antibody Understanding

Anti-CD279 (PD-1) Antibody: Overview

PD-1, a protein expressed on T cells, is a member of the CD28 superfamily, and it transmits coinhibitory signals upon engagement with its ligands PD-L1 and PD-L2. Accumulating evidence suggests that the PD-1 system plays pivotal roles in the regulation of autoimmunity, transplantation immunity, infectious immunity, and tumor immunity. Because the interaction of PD-1 with its ligands occurs in the effector phase of killer T cell responses in peripheral blood, anti-PD-1 and anti-PD-L1 monoclonal antibodies are ideal as specific agents to augment T cell responses to tumors with fewer adverse events than with the inhibition of CTLA-4, because the interaction of CTLA-4 with its ligands occurs in the priming phase of T cell responses within lymph nodes. The tolerability of PD-1-pathway blockers and their unique mechanism of action have made them ideal backbones for combination regimen development. Combination approaches involving cytotoxic chemotherapy, anti-angiogenic agents, alternative immune-checkpoint inhibitors, immunostimulatory cytokines and cancer vaccines are currently under clinical investigation.

Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Anti-CD279 (PD-1) Antibody pipeline landscape is provided which includes the disease overview and Anti-CD279 (PD-1) Antibody treatment guidelines. The assessment part of the report embraces, in depth Anti-CD279 (PD-1) Antibody commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Anti-CD279 (PD-1) Antibody collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Anti-CD279 (PD-1) Antibody R&D. The therapies under development are focused on novel approaches to treat/improve Anti-CD279 (PD-1) Antibody.

Anti-CD279 (PD-1) Antibody Emerging Drugs Chapters

This segment of the Anti-CD279 (PD-1) Antibody report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Anti-CD279 (PD-1) Antibody Emerging Drugs

IBI308: Innovent Biologics IBI308/ Sintilimab is a fully human monoclonal antibody that blocking programmed death protein-1. Innovent holds the global intellectual property rights of IBI308. Currently IBI308 has been approved for marketing by the NMPA. Acting as an immune checkpoint inhibitor by targeting PD-1, IBI308 boosts the immune response against tumor cells and inhibits the immune escape of tumor cells. It is currently in Phase III for Acral Melanoma, Nasopharyngeal Neoplasms, and Gastric Cancer. It is being developed by InnoventBiologics.

Tislelizumab: Bei GeneTislelizumab (BGB-A317) is a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to Fc?R on macrophages. In pre-clinical studies, binding to Fc?R on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologiccancers.

Anti-CD279 (PD-1) Antibody: Therapeutic Assessment

This segment of the report provides insights about the different Anti-CD279 (PD-1) Antibody drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Anti-CD279 (PD-1) Antibody

There are approx. 40+ key companies which are developing the therapies for Anti-CD279 (PD-1) Antibody. The companies which have their Anti-CD279 (PD-1) Antibody drug candidates in the most advanced stage, i.e. Phase III include, Innovent Biologics.

Phases

This report covers around 40+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Anti-CD279 (PD-1) Antibody pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Anti-CD279 (PD-1) Antibody: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anti-CD279 (PD-1) Antibody therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anti-CD279 (PD-1) Antibody drugs.

Anti-CD279 (PD-1) Antibody Report Insights

• Anti-CD279 (PD-1) Antibody Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Anti-CD279 (PD-1) Antibody Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Anti-CD279 (PD-1) Antibody drugs?
• How many Anti-CD279 (PD-1) Antibody drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Anti-CD279 (PD-1) Antibody?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Anti-CD279 (PD-1) Antibody therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Anti-CD279 (PD-1) Antibody and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• GlaxoSmithKline
• Innovent Biologics
• BeiGene
• Shanghai Junshi Biosciences

Key Products

• Dostarlimab
• Sintilimab
• Tislelizumab
• JS-003
• JS-201
• Toripalimab

This product will be delivered within 2-4 business days.